ʻAukake21,Ua hāʻawi ʻia ka loiloi mua no ka bispecific T cell engager, ʻo epcoritamab, e ke Center for Drug Evaluation (CDE) o ka National Medical Products Administration (NMPA). Kuhi ʻia ka ʻae ʻia i nā poʻe maʻi makua me ka relapsed a refractory follicular lymphoma (FL), kahi ʻāpana nui o nā maʻi ʻino o nā cell B.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
E pili ana iā Epcoritamab
ʻO Epcoritamab kahi antibody IgG1-bispecific i hana ʻia me ka hoʻohana ʻana i ka ʻenehana DuoBody ponoʻī a Genmab a lawelawe ʻia ma lalo o ka ʻili. Ua hoʻolālā ʻia ka ʻenehana DuoBody-CD3 a Genmab e kuhikuhi pololei i nā pūnaewele T cytotoxic e hoʻopuka i kahi pane pale i nā ʻano pūnaewele i manaʻo ʻia. Ua hoʻolālā ʻia ʻo Epcoritamab e hoʻopaʻa like i ka CD3 ma nā pūnaewele T a me CD20 ma nā pūnaewele B a hoʻoulu i ka pepehi ʻana o nā pūnaewele CD20+ i hoʻopili ʻia e nā pūnaewele T.
E pili ana i ka Lymphoma Follicular (FL)
ʻO ka FL maʻamau he ʻano palaualelo (a lohi paha ka ulu ʻana) o ka lymphoma non-Hodgkin (NHL) e kū mai ana mai nā lymphocytes B a ʻo ia ka lua o ke ʻano maʻamau o ka NHL e helu ana no 20-30 pakeneka o nā hihia āpau.i Ma kahi o 15,000 mau kānaka e hoʻomohala i ka FL i kēlā me kēia makahiki ma USii a ua manaʻo ʻia he hiki ʻole ke hoʻōla ʻia me nā maʻi mālama maʻamau o kēia manawa.iii Hoʻi hou pinepine nā maʻi a, me kēlā me kēia hoʻi hou ʻana, ʻoi aku ka pōkole o ke kala ʻana a me ka manawa i ka lāʻau aʻe.iv I ka hala ʻana o ka manawa, hiki ke hana ʻia ka hoʻololi ʻana i ka lymphoma B-cell nui diffuse (DLBCL), kahi ʻano hoʻouka kaua o NHL e pili ana me nā hopena ola maikaʻi ʻole, ma mua o 25 pakeneka o nā maʻi FL.
ʻEPCORE FL-1 (NCT05409066) he hoʻokolohua hana komo ākea Phase 3 e loiloi i ka palekana a me ka pono o epcoritamab me rituximab a me lenalidomide (R2) e kūʻē iā R2 wale nō i nā poʻe maʻi me ka lymphoma follicular relapsed/refractory (R/R) (FL).
ʻAukake 7,Genmab A/Sua hoʻolaha i nā hopena maikaʻi o ka hoʻokolohua Phase 3 EPCORE FL-1 e loiloi ana i ka subcutaneous epcoritamab, kahi antibody bispecific, i hui pū ʻia me rituximab a me lenalidomide (R®2) e kūʻē iā R2 wale nō no ka mālama ʻana i nā maʻi makua me ka lymphoma follicular relapsed a refractory (R/R) (FL). Ua hālāwai ke aʻo ʻana me kāna mau hopena mua ʻelua o ka helu pane holoʻokoʻa (ORR, p-value < 0.0001) a me ke ola ʻole o ka holomua (PFS, HR 0.21, p-value < 0.0001), e hōʻike ana i nā ʻokoʻa koʻikoʻi a me ke ʻano lapaʻau i nā hopena ʻelua, e hōʻemi ana i ka pilikia o ka holomua o ka maʻi a i ʻole ka make ma 79%.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ka manawa hoʻouna: Sep-05-2025